Unusual symptoms for tamoxifen-associated maculopathy;Ungewöhnliches Erscheinungsbild einer tamoxifenassoziierten Makulopathie

Ophthalmologe

Volumn 107, Issue 8, 2010, Pages 750-752

  Hager, T ^a   Hoffmann, S ^a   Seitz, B ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Drug associated retinopathy; Foveolar cyst; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

ARTICLE; BONE TUMOR; BREAST TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; CRYSTALLIZATION; CYST; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LONG TERM CARE; METASTASIS; MIDDLE AGED; OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHOTORECEPTOR CELL; RETINA DISEASE; VISUAL ACUITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; CRYSTALLIZATION; CYSTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; LONG-TERM CARE; MIDDLE AGED; OPHTHALMOSCOPES; PHOTORECEPTOR CELLS, VERTEBRATE; RETINAL DISEASES; TAMOXIFEN; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 77955854010     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2150-7     Document Type: Article

References (19)

1. Adamus G, Machnicki M, Seigel GM (1997) Apoptotic retinal cell death induced by autoantibodies of cancer associated retinopathy. IOVS 38: 283-291.
2. Adamus G (2009) Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 8(5): 410-414.
3. Alwitry A, Gardner I (2002) Tamoxifen maculopathy. Arch Ophthalmol 120: 1402.
4. Baget-Bernaldiz M, Soler Lluis N, Romero-Aroca P, Traveset-Maeso A (2008) Optical coherence tomography study in tamoxifen maculopathy. Arch Soc Esp Oftalmol 83: 615-618.
5. Bentley CR, Davies G, Aclimandos WA (1992) Tamoxifen retinopathy: a rare but serious complication. BMJ 304: 495-496.
6. Bernstein PS, DellaCroce JT (2007) Diagnostic & therapeutic challenges. Tamoxifen toxicity. Retina 27(7): 982-988.
7. Bourla TH, Gonzales CR, Mango CW et al (2007) Intravitreous VEGF inhibitor therapy for tamoxifen induced macular edema. Semin Ophthalmol 22: 87-88.
8. Brauch H, Mürdter TE, Eichelbaum M, Schwab M (2009) Pharmacogenomics of tamoxifen therapy. Clin Chem 55: 1770-1782.
9. Cronin BG, Lekich CK, Bourke RD (2005) Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol 26: 101-105.
10. De Potter P, Disneur D, Levecq L, Snyers B (2002) Ocular manifestations of cancer. J Fr Ophtalmol 25(2): 194-202.
11. Gianni L, Panzini I, Li S et al (2006) Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from international breast cancer study group trials. Cancer 106: 505-513.
12. Gualino V, Cohen SY, Delyfer M et al (2005) Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol 140: 757-758.
13. Inada ET, Watanabe KP, Tanaka SG, Sakakisbara LA (2005) Toxicidade ocular causada pelo tamoxifeno: relato de casa. Arq Bras Oftalmol 68: 554-556.
14. Link B, Schlötzer-Schrehardt U, Jünemann A (2009) Carcinoma-associated retinopathy - an electrophysiological and immunhistochemical correlation. Retina 29: 69-72.
15. Marmor MF, Fulton AB, Holder GE et al (2009) Standard for clinical electroretinography (2008 update). Doc Ophthalmol 118: 69-77.
16. Noureddin BN, Seoud M, Bashshur Z et al (1999) Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 13: 729-733.
17. Ritter C, Renner AB, Wachtlin J et al (2008) Tamoxifen-Retinopathie. Ophthalmologe 105: 544-549.
18. Sobottka B, Scholte T, Besch D et al (2000) Cancer-associated retinopathy. A review article with some clinical examples. Klin Monat Augenheilkd 216: 17-24.
19. Zinchuk O, Watanabe M, Hayashi N et al (2006) A case of tamoxifen keratopathy. Arch Ophthalmol 124: 1046-1048.